Erdosteine

Grey

Brand Name(s):Erdotin

Indication:All licensed indications

Rationale:2

Considered:Apr-09

Review Date:Jul-20

Comments:
Erdosteine is not considered suitable for prescribing. Current clinical evidence for the efficacy of erdosteine for its licensed indication is weak, with no evidence for improved clinical outcomes or quality
of life. Its place in therapy for acute exacerbations of chronic bronchitis is unclear. NICE guidelines recommend the use of mucolytic drugs for longer-term use in stable chronic obstructive pulmonary disease. Mucolytic drugs are not mentioned for the treatment of acute exacerbations.

Erdosteine (Erdotin) for acute exacerbations of chronic bronchitis
MTRAC Verdict & Summary November 2007

Oral mucolytic agent indicated for the short-term treatment of acute exacerbations of chronic bronchitis in adults. It is licensed to be used for a maximum ten day course. Published evidence to support the efficacy of erdosteine in treating acute exacerbations is not robust. The trials do not reflect current UK practice for the management of COPD, with concurrent use of corticosteroids & anticholinergics frequently not permitted. (UKMi New Medicines Profile; Erdosteine; issue 07/05; May 2007)